BETRF (BetterLife Pharma) Total Liabilities : $5.03 Mil (As of Oct. 2024)

View and export this data going back to 2010. Start your Free Trial

What is BetterLife Pharma Total Liabilities?

BetterLife Pharma's Total Liabilities for the quarter that ended in Oct. 2024 was $5.03 Mil.

BetterLife Pharma's quarterly Total Liabilities declined from Apr. 2024 ($6.27 Mil) to Jul. 2024 ($5.85 Mil) and declined from Jul. 2024 ($5.85 Mil) to Oct. 2024 ($5.03 Mil).

BetterLife Pharma's annual Total Liabilities increased from Jan. 2022 ($4.00 Mil) to Jan. 2023 ($5.67 Mil) and increased from Jan. 2023 ($5.67 Mil) to Jan. 2024 ($5.98 Mil).

BetterLife Pharma Total Liabilities Historical Data

The historical data trend for BetterLife Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma Total Liabilities Chart

BetterLife Pharma Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

Total Liabilities

Get a 7-Day Free Trial

4.27

4.70

4.00

5.67

5.98

BetterLife Pharma Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
Total Liabilities	Get a 7-Day Free Trial															5.24	5.98	6.27	5.85	5.03

BetterLife Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BetterLife Pharma's Total Liabilities for the fiscal year that ended in Jan. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.086	+	(0.685	+	0.205
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	5.98

Total Liabilities	=	Total Assets (A: Jan. 2024 )	-	Total Equity (A: Jan. 2024 )
	=	0.242	-	-5.733
	=	5.98

BetterLife Pharma's Total Liabilities for the quarter that ended in Oct. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.268	+	(0.588	+	0.172
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	5.03

Total Liabilities	=	Total Assets (Q: Oct. 2024 )	-	Total Equity (Q: Oct. 2024 )
	=	0.197	-	-4.83
	=	5.03

BetterLife Pharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BetterLife Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (OTCPK:BETRF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

NPAU:Germany NPAU:Germany BETR:Canada

Address

1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6

Website

https://www.abetterlifepharma.com

BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and the European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.

Executives

Barbara-jean Anne Bormann-kennedy	director, officer: President	1188 BROADWAY, SUITE 306, SOMERVILLE MA 02144
Moira Ong	officer: Chief Financial Officer	2392 LAWSON AVENUE, WEST VANCOUVER A1 V7V 2E6
Hassan Salari	director, 10 percent owner	1517 WEST 58TH AVENUE, VANCOUVER A1 V6P 1W6
Ahmad Doroudian	director, officer: Chairman	1275 WEST 6TH AVENUE, VANCOUVER A1 V6H 1A6